Chai Discovery raises $400M Series C at $3.8B valuation; AI drug discovery reaches pharma scale

Chai Discovery, a two-year-old AI molecular design company founded by ex-OpenAI and Meta researchers, raised $400 million in Series C funding led by Index Ventures, Kleiner Perkins, Sequoia Capital and Dimension, valuing the company at $3.8 billion. The round brings total funding to ~$630 million. The oversubscribed round included participation from OpenAI and Thrive Capital, signaling institutional confidence in AI-driven drug discovery as a commercial rather than speculative category.

Chai's AI models (Chai-3 being the latest) generate novel molecular designs from scratch and achieve double-digit hit rates in de novo antibody design—16% on Chai-2 compared to single-digit rates for prior computational methods. The company is already deployed at scale with Eli Lilly, Pfizer, and Novartis, using the platform to target molecules that traditional discovery methods have struggled to reach.

Founded in 2024, Chai exemplifies how AI has shifted from promise to production in drug discovery. Investors cited the team's velocity and real-world pharma partnerships as decisive factors. For architects: this is a Data + AI play where a narrow, deep vertical (molecular design) now commands multi-billion valuations when anchored to credible customer deployments and measurable improvements in success rates.